Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

The goal of this study was to examine the effects of semaglutide on change in NYHA functional class over time.

The researchers also investigated the effects of semaglutide on HF-related symptoms, physical limitations, and bodyweight and other trial endpoints across baseline NYHA functional class categories.

Who Took Part

The abstract describes 1,145 participants taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

The outcome of interest for this analysis was the change in NYHA functional class (baseline to 52 weeks).

The researchers also investigated the effects of semaglutide on the dual primary, confirmatory secondary, and selected exploratory endpoints according to baseline NYHA functional class.

What Was Measured

PubMed files the paper under topics including Heart Failure, Glucagon-Like Peptides, Stroke Volume, Obesity, Hypoglycemic Agents and Semaglutide.

Author keywords: New York Heart Association functional class and left ventricular ejection fraction.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 1,145 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Journal of the American College of Cardiology), a journal based in United States.

More context: the Semaglutide compound page, all human trials.